Cogent Biosciences (COGT) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.50
- EPS estimate
- −$0.52
- EPS surprise
- +3.19%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 3, 2025
The most recent quarter in the table is Q3 2025, which Cogent Biosciences reported on November 3, 2025. The loss was $0.50 per share, slightly better than the expected loss of $0.52, a 3.19% beat. No revenue was reported and no revenue estimate was given. A year earlier, in Q3 2024, the loss was $0.64 per share.
Every one of the 20 quarters in the table was a loss. Full-year losses were $1.85 per share in 2021, $2.45 in 2022, $2.40 in 2023 and $2.46 in 2024. The first three quarters of 2025 add up to a loss of $1.67, narrower than the $1.85 of the same period in 2024. Since Q4 2021, quarterly losses have stayed between $0.50 and $0.71 per share. The largest loss in the table, $6.06, came in Q4 2020, the oldest row. Cogent beat the EPS estimate only 5 times in 20 quarters.
The table has no results after Q3 2025. In past years, Cogent reported fourth-quarter results between late February and mid-March, and third-quarter results between early and mid-November. The next update to the table will show whether losses kept narrowing after Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 3, 2025 | −$0.52 | −$0.50 | +3.19% | $0.00 | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.59 | −$0.53 | +9.71% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$0.59 | −$0.64 | −7.17% | $0.00 | SEC |
| Q4 2024 | Feb 25, 2025 | −$0.61 | −$0.61 | −0.25% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.57 | −$0.64 | −13.03% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.56 | −$0.59 | −5.92% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.51 | −$0.62 | −20.51% | $0.00 | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.56 | −$0.63 | −11.82% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.50 | −$0.64 | −27.72% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.54 | −$0.59 | −8.38% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.57 | −$0.54 | +5.48% | $0.00 | SEC |
| Q4 2022 | Mar 14, 2023 | −$0.52 | −$0.56 | −8.30% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.51 | −$0.50 | +2.59% | $0.00 | — |
| Q2 2022 | Aug 9, 2022 | −$0.66 | −$0.71 | −8.12% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.61 | −$0.68 | −12.40% | $0.00 | SEC |
| Q4 2021 | Mar 15, 2022 | −$0.52 | −$0.60 | −14.50% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.45 | −$0.48 | −6.67% | $0.00 | SEC |
| Q2 2021 | Aug 16, 2021 | −$0.36 | −$0.43 | −20.55% | $0.00 | SEC |
| Q1 2021 | May 12, 2021 | −$0.42 | −$0.34 | +18.07% | $0.00 | SEC |
| Q4 2020 | Mar 16, 2021 | −$0.51 | −$6.06 | −1088.24% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Cogent Biosciences (COGT) last report earnings?
Cogent Biosciences last reported on Nov 3, 2025, covering fiscal Q3 2025.
Did COGT beat earnings estimates?
Yes. Cogent Biosciences reported EPS of −$0.50 for Q3 2025 against a −$0.52 estimate — a 3.19% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.